Hims & Hers Health shares are rebounding despite facing a potential FTC lawsuit over alleged data sharing and deceptive practices. The stock's bounce is attributed to technical support at its 100-day SMA, though overhead resistance and negative momentum indicators suggest a challenging path ahead.
Hims & Hers Health is experiencing a rebound in its stock price, driven by technical support around its 100-day SMA, despite significant negative news. The company is facing a potential FTC lawsuit alleging unlawful sharing of sensitive customer health data with advertisers like Meta Platforms and Snap Inc., and deceptive billing practices. This legal challenge, coupled with Jim Cramer's 'controversial' label, creates significant sentiment headwinds. While the short-term bounce suggests some resilience, the long-term implications of an FTC lawsuit and ongoing negative analyst sentiment could cap future rallies, making the $30 resistance level crucial for traders to watch.